Debt-to-equity in % of Unicycive Therapeutics, Inc. from Q1 2022 to Q3 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Unicycive Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q3 2025.
Unicycive Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2025 was 93.1 %.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Unicycive Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	93.1	+196		Sep 30, 2025
Q2 2025	896	+1.09K		Jun 30, 2025
Q1 2025	-271	-88.3	-48.4%	Mar 31, 2025
Q4 2024	-132	+59.4	+31%	Dec 31, 2024
Q3 2024	-103	+62.7	+38%	Sep 30, 2024
Q2 2024	-197	-59.4	-43.3%	Jun 30, 2024
Q1 2024	-183	+2.63K	+93.5%	Mar 31, 2024
Q4 2023	-192	-244	-467%	Dec 31, 2023
Q3 2023	-165	-195	-653%	Sep 30, 2023
Q2 2023	-137	-152	-1050%	Jun 30, 2023
Q1 2023	-2.81K	-2.83K	-11814%	Mar 31, 2023
Q4 2022	52.2			Dec 31, 2022
Q3 2022	29.9			Sep 30, 2022
Q2 2022	14.4			Jun 30, 2022
Q1 2022	24			Mar 31, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.